肿瘤防治研究2024，Vol.51Issue(8)：648-654,7.DOI:10.3971/j.issn.1000-8578.2024.24.0301
T系白血病的CAR-T治疗:进展、困境和未来出路
CAR-T Therapy for T-lineage Leukemia:Progress,Dilemmas,and Way Forward
摘要
Abstract
Tumor immunotherapy occupies a pivotal position in the field of hematological malignancies.Chimeric antigen receptor(CAR)T-cell therapy has established a new therapeutic pattern for hematological immunotherapy and achieved satisfactory clinical results in the treatment of B-lineage hematological malignancies.However,CAR T-cell therapy has some limitations in the treatment of T-cell acute lymphoblastic leukemia because of the presence of CAR T-cell fratricide,tumor cell contamination,T-cell aplasia,and other clinically relevant problems.Therefore,the current major challenge is overcoming the existing bottlenecks to optimize CAR-T therapy and improve its efficacy against T-ALL while improving the prognosis of patients.关键词
细胞免疫疗法/CAR-T细胞疗法/急性T淋巴细胞白血病Key words
Cellular immunotherapy/Chimeric antigen receptor T-cell thera-py/T-cell acute lymphoblastic leukemia分类
医药卫生引用本文复制引用
韩雅静,赵丽平,唐凯婷,牛卿,潘静,冯晓明..T系白血病的CAR-T治疗:进展、困境和未来出路[J].肿瘤防治研究,2024,51(8):648-654,7.基金项目
国家重点研发计划(2021YFA1100703) （2021YFA1100703）
天津市科技计划项目(21JCQNJC01750) National Key R&D Program of China(No.2021YFA1100703) （21JCQNJC01750）
Tian-jin Municipal Science and Technology Commission Grant(No.21JCQNJC01750) （No.21JCQNJC01750）
